PLIANT THERAPEUTICS, INC. Capital Expenditures
PLIANT THERAPEUTICS, INC. (PLRX) reported Capital Expenditures of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $374.00K, a 90.28% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $3.85M, a 317.81% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $921.00K, a 47.67% decline from fiscal 2022.
- PLIANT THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $1.76M, a 9.88% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | $112.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $112.00K derived: sum of 3 quarters · filed 2026-08-11 | $374.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $112.00K derived: sum of 2 quarters · filed 2026-08-11 | $374.00K 10-Q · filed 2025-11-06 | $583.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $374.00K 10-Q · filed 2026-08-11 | $583.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $262.00K 10-Q · filed 2026-05-11 | $471.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.37M derived: sum of 3 quarters · filed 2026-05-11 | $2.62M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.10M derived: sum of 2 quarters · filed 2026-03-11 | $2.36M derived: sum of 3 quarters · filed 2026-03-11 | $3.85M 10-K · filed 2026-03-11 |
| 2024-09-30 | $896.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.15M derived: sum of 2 quarters · filed 2025-11-06 | $3.64M 10-Q · filed 2025-11-06 | $3.70M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.74M 10-Q · filed 2025-08-07 | $2.80M derived: sum of 3 quarters · filed 2025-08-07 | $2.90M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.49M 10-Q · filed 2025-05-08 | $1.55M derived: sum of 2 quarters · filed 2025-05-08 | $1.65M derived: sum of 3 quarters · filed 2025-05-08 | $2.25M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $155.00K derived: sum of 2 quarters · filed 2025-03-03 | $758.00K derived: sum of 3 quarters · filed 2025-03-03 | $921.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $697.00K derived: sum of 2 quarters · filed 2024-11-07 | $860.00K 10-Q · filed 2024-11-07 | $1.03M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $603.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $766.00K 10-Q · filed 2024-08-07 | $932.00K derived: sum of 3 quarters · filed 2025-03-03 | $1.63M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $163.00K 10-Q · filed 2024-05-06 | $329.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.02M derived: sum of 3 quarters · filed 2025-03-03 | $1.28M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $862.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.12M derived: sum of 3 quarters · filed 2025-03-03 | $1.76M 10-K · filed 2025-03-03 |
| 2022-09-30 | $696.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $950.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.59M 10-Q · filed 2023-11-09 | $2.19M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $254.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $898.00K 10-Q · filed 2023-08-09 | $1.49M derived: sum of 3 quarters · filed 2024-02-27 | $1.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $644.00K 10-Q · filed 2023-05-09 | $1.24M derived: sum of 2 quarters · filed 2024-02-27 | $1.72M derived: sum of 3 quarters · filed 2024-02-27 | $2.35M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $592.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.07M derived: sum of 2 quarters · filed 2024-02-27 | $1.71M derived: sum of 3 quarters · filed 2024-02-27 | $1.95M 10-K · filed 2024-02-27 |
| 2021-09-30 | $480.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.12M derived: sum of 2 quarters · filed 2022-11-08 | $1.36M 10-Q · filed 2022-11-08 | $1.95M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $639.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $881.00K 10-Q · filed 2022-08-08 | $1.47M derived: sum of 3 quarters · filed 2022-08-08 | $1.79M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $242.00K 10-Q · filed 2022-05-09 | $829.00K derived: sum of 2 quarters · filed 2022-05-09 | $1.15M derived: sum of 3 quarters · filed 2022-05-09 | $1.44M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $587.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $910.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.20M derived: sum of 3 quarters · filed 2022-03-01 | $1.53M 10-K · filed 2022-03-01 |
| 2020-09-30 | $323.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $609.00K derived: sum of 2 quarters · filed 2021-11-09 | $945.00K 10-Q · filed 2021-11-09 | $1.13M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $286.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $622.00K 10-Q · filed 2021-08-09 | $806.00K derived: sum of 3 quarters · filed 2022-03-01 | $854.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $336.00K 10-Q · filed 2021-05-10 | $520.00K derived: sum of 2 quarters · filed 2022-03-01 | $568.00K derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $232.00K derived: sum of 2 quarters · filed 2022-03-01 | $964.00K 10-K · filed 2022-03-01 | |
| 2019-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $780.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $732.00K 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |